Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients

Research output: Contribution to journalArticle

Abstract

Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We studied 55 patients with multiple myeloma (MM) who received bortezomib as first line therapy and 70 pre-treated patients who received bortezomib in relapse or progression. Regarding PN, no differences were found among untreated and pre-treated patients in the incidence (55% vs 52%, p = 0.43), severity (NCI grade 3-4 9% vs 14%, p = 0.27), and outcome (improved/resolved 90% vs 91%, p = 0.58). Concerning neuropathic pain, the incidence was lower (50% vs 81%, p = 0.008) and solved earlier (35 days vs 91 days, p = 0.02) in untreated compared with pre-treated patients. Untreated patients needed dose modification less frequently (36% vs 73%, p = 0.012). No correlation was found between development of PN and prior exposure to potentially neurotoxic drugs such as thalidomide, vincristine, and cysplatin. Age represented the main risk factor for PN (p = 0.036) with an increase in risk of PN amounting to 6% per year of age. In conclusion, incidence, severity and outcome of bortezomib-related PN are similar in untreated and pre-treated MM patients except for neuropathic pain which has lower incidence and shorter duration in untreated patients with less frequent need for bortezomib discontinuation. Age emerges as the most relevant risk factor for peripheral neuropathy, with a risk increase for PN of 6% per year of age.

Original languageEnglish
Pages (from-to)471-474
Number of pages4
JournalLeukemia Research
Volume34
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Peripheral Nervous System Diseases
Multiple Myeloma
Neuralgia
Incidence
Bortezomib
Recurrence
Proteasome Inhibitors
Thalidomide
Vincristine

Keywords

  • Bortezomib
  • Peripheral neuropathy
  • Relapsed refractory myeloma
  • Untreated patients

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

@article{ad042be44d95445b96757b7f8866097c,
title = "Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients",
abstract = "Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We studied 55 patients with multiple myeloma (MM) who received bortezomib as first line therapy and 70 pre-treated patients who received bortezomib in relapse or progression. Regarding PN, no differences were found among untreated and pre-treated patients in the incidence (55{\%} vs 52{\%}, p = 0.43), severity (NCI grade 3-4 9{\%} vs 14{\%}, p = 0.27), and outcome (improved/resolved 90{\%} vs 91{\%}, p = 0.58). Concerning neuropathic pain, the incidence was lower (50{\%} vs 81{\%}, p = 0.008) and solved earlier (35 days vs 91 days, p = 0.02) in untreated compared with pre-treated patients. Untreated patients needed dose modification less frequently (36{\%} vs 73{\%}, p = 0.012). No correlation was found between development of PN and prior exposure to potentially neurotoxic drugs such as thalidomide, vincristine, and cysplatin. Age represented the main risk factor for PN (p = 0.036) with an increase in risk of PN amounting to 6{\%} per year of age. In conclusion, incidence, severity and outcome of bortezomib-related PN are similar in untreated and pre-treated MM patients except for neuropathic pain which has lower incidence and shorter duration in untreated patients with less frequent need for bortezomib discontinuation. Age emerges as the most relevant risk factor for peripheral neuropathy, with a risk increase for PN of 6{\%} per year of age.",
keywords = "Bortezomib, Peripheral neuropathy, Relapsed refractory myeloma, Untreated patients",
author = "Alessandro Corso and Silvia Mangiacavalli and Marzia Varettoni and Cristana Pascutto and Patrizia Zappasodi and Mario Lazzarino",
year = "2010",
month = "4",
doi = "10.1016/j.leukres.2009.07.022",
language = "English",
volume = "34",
pages = "471--474",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "4",

}

TY - JOUR

T1 - Bortezomib-induced peripheral neuropathy in multiple myeloma

T2 - A comparison between previously treated and untreated patients

AU - Corso, Alessandro

AU - Mangiacavalli, Silvia

AU - Varettoni, Marzia

AU - Pascutto, Cristana

AU - Zappasodi, Patrizia

AU - Lazzarino, Mario

PY - 2010/4

Y1 - 2010/4

N2 - Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We studied 55 patients with multiple myeloma (MM) who received bortezomib as first line therapy and 70 pre-treated patients who received bortezomib in relapse or progression. Regarding PN, no differences were found among untreated and pre-treated patients in the incidence (55% vs 52%, p = 0.43), severity (NCI grade 3-4 9% vs 14%, p = 0.27), and outcome (improved/resolved 90% vs 91%, p = 0.58). Concerning neuropathic pain, the incidence was lower (50% vs 81%, p = 0.008) and solved earlier (35 days vs 91 days, p = 0.02) in untreated compared with pre-treated patients. Untreated patients needed dose modification less frequently (36% vs 73%, p = 0.012). No correlation was found between development of PN and prior exposure to potentially neurotoxic drugs such as thalidomide, vincristine, and cysplatin. Age represented the main risk factor for PN (p = 0.036) with an increase in risk of PN amounting to 6% per year of age. In conclusion, incidence, severity and outcome of bortezomib-related PN are similar in untreated and pre-treated MM patients except for neuropathic pain which has lower incidence and shorter duration in untreated patients with less frequent need for bortezomib discontinuation. Age emerges as the most relevant risk factor for peripheral neuropathy, with a risk increase for PN of 6% per year of age.

AB - Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We studied 55 patients with multiple myeloma (MM) who received bortezomib as first line therapy and 70 pre-treated patients who received bortezomib in relapse or progression. Regarding PN, no differences were found among untreated and pre-treated patients in the incidence (55% vs 52%, p = 0.43), severity (NCI grade 3-4 9% vs 14%, p = 0.27), and outcome (improved/resolved 90% vs 91%, p = 0.58). Concerning neuropathic pain, the incidence was lower (50% vs 81%, p = 0.008) and solved earlier (35 days vs 91 days, p = 0.02) in untreated compared with pre-treated patients. Untreated patients needed dose modification less frequently (36% vs 73%, p = 0.012). No correlation was found between development of PN and prior exposure to potentially neurotoxic drugs such as thalidomide, vincristine, and cysplatin. Age represented the main risk factor for PN (p = 0.036) with an increase in risk of PN amounting to 6% per year of age. In conclusion, incidence, severity and outcome of bortezomib-related PN are similar in untreated and pre-treated MM patients except for neuropathic pain which has lower incidence and shorter duration in untreated patients with less frequent need for bortezomib discontinuation. Age emerges as the most relevant risk factor for peripheral neuropathy, with a risk increase for PN of 6% per year of age.

KW - Bortezomib

KW - Peripheral neuropathy

KW - Relapsed refractory myeloma

KW - Untreated patients

UR - http://www.scopus.com/inward/record.url?scp=76749127007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749127007&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.07.022

DO - 10.1016/j.leukres.2009.07.022

M3 - Article

C2 - 19674790

AN - SCOPUS:76749127007

VL - 34

SP - 471

EP - 474

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -